# A rapid strategy to develop personalized cancer nanovaccines for different immunogenic tumors.

https://mdr.nims.go.jp/datasets/2f1dbce1-792e-4688-afca-8b1478a4a8f7

## File

- [2024  J Clin Oncol -Xia Li (MDR).pdf](https://mdr.nims.go.jp/filesets/f467e6d1-8cd8-4ff7-8a3d-61494646bb37/download) ([Detail](https://mdr.nims.go.jp/filesets/f467e6d1-8cd8-4ff7-8a3d-61494646bb37.md))

## Id

2f1dbce1-792e-4688-afca-8b1478a4a8f7

## Local identifier



## Visibility

open_to_public

## State

published

## Created at

2024-09-17T08:23:52.879171Z

## Updated at

2025-05-29T23:30:07.827050Z

## Published at

2025-05-29T23:17:58.727078Z

## Doi

https://doi.org/10.48505/nims.4762

## First published url

https://doi.org/10.1200/jco.2024.42.16_suppl.e14670

## Date published

2024-06-01

## Recorded date published

2024-6-1

## Resource type

journal_article

## Manuscript type

accepted_manuscript

## Collection



## Title

- title: A rapid strategy to develop personalized cancer nanovaccines for different
    immunogenic tumors.
  title_type: original
  lang: en

## Description

- description: Therapeutic cancer vaccines aim to train the immune system and elicit
    antitumor immune responses, which are expected to fill the unmet medical need
    of immune checkpoint inhibitors. Despite tremendous efforts over the past decades,
    it remains challenging to prepare personalized cancer vaccines using a facile
    and rapid approach due to tumor diversity. CpG-ODN is a promising immunoadjuvant
    in cancer immunotherapy, and many clinical trials have been performed or are ongoing.
    However, commonly used phosphorothioate-modified CpG ODN easily induces protein
    aggregation and its long-term side effects are concerned. Here, we designed hollow
    large-pore mesoporous organosilica with sulfide bond to simultaneously load unmodified
    CpG-ODN with guanine-quadruplex (G4) structures and different tumor antigens to
    prepare personalized cancer vaccines in a simple, fast, and effective way.
  description_type: abstract
  lang: und

## Creator

- name: Xia Li
  role: author
  orcid: https://orcid.org/0000-0002-3246-4462
  organization: National Institute for Materials Science
  ror: https://ror.org/026v1ze26
- name: Naoto Shirahata
  role: author
  orcid: https://orcid.org/0000-0002-1217-7589
  organization: National Institute for Materials Science
  ror: https://ror.org/026v1ze26
- name: Tomohiko Yamazaki
  role: author
  orcid: https://orcid.org/0000-0003-2136-8042
  organization: National Institute for Materials Science
  ror: https://ror.org/026v1ze26
- name: Nobutaka Hanagata
  role: author
  orcid: https://orcid.org/0000-0001-6079-3426
  organization: National Institute for Materials Science
  ror: https://ror.org/026v1ze26

## Contact agent



## Publisher

organization: American Society of Clinical Oncology (ASCO)

## Managing organization



## Keyword

- subject: personalized
  schema: not_defined
- subject: cancer nanovaccines
  schema: not_defined
- subject: CpG-ODN
  schema: not_defined
- subject: mesoporous organosilica
  schema: not_defined

## Rights

- identifier: http://rightsstatements.org/vocab/InC/1.0/

## Other identifier(s)



## Data origin

- data_origin_type: other

## Embargo

start_date: 2024-05-29
end_date: 2025-05-29

## Journal

- title: Journal of Clinical Oncology
  issn: '0732183X'
  volume: '42'
  issue: 16_suppl

## Conference



## Related item



## Funding

- identifier: 23K04555 and 22K20517
  funder_name: Japan Society for the Promotion of Science (JSPS), KAKENHI
- funder_name: NIMS

## Instrument



## Instrument operator



## Instrument managing organization



## Measurement method



## Specimen



## Chemical composition



## Structure for specimen



## Structural feature for specimen



## Specific property for specimen



## Process for specimen treatment



## Computational method



## Energy level/transition state



## Software



## Custom property



## Fileset

- id: f467e6d1-8cd8-4ff7-8a3d-61494646bb37
  filename: 2024  J Clin Oncol -Xia Li (MDR).pdf
  content_type: application/pdf
  size: 95077
  md5: dd96abd7175fdf6b1d083baea2f5a02f

## Thumbnail

fileset_id: f467e6d1-8cd8-4ff7-8a3d-61494646bb37
filename: 2024  J Clin Oncol -Xia Li (MDR).pdf